Background: Photodynamic therapy (PDT) with Metvix® is a good therapeutic option to treat actinic keratosis, but it presents drawbacks (pain, lesion recurrences, heterogeneous outcome), emphasizing the possible need to individualize treatment. Objective: We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching. Methods: 25 patients were treated by Metvix PDT. The outcome was evaluated after 1.3 (±0.4), 7.6 (±1.8), 13.2 (±1.2) and 33.6 (±3.0) months. After administration of Metvix, red light (632 ± 10 nm) was delivered with a light-emitting diode panel device. The outcome was assessed on a cosmetoclinical scale. Results: All patients who showed a fluorescence level before PDT treatment above a certain threshold had a complete recovery at 33.6 (±3.0) months. Conclusion: Our approach could be used to individualize PDT treatment based on the pretreatment fluorescence level, and to predict its long-term outcome.

1.
Yantsos VA, Conrad N, Zabawski E, Cockerell CJ: Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999;18:3-14.
2.
Ackerman AB, Mones JM: Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006;155:9-22.
3.
Dinehart SM: The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:s25-s28.
4.
Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, Yamauchi PS: Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227-232.
5.
Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM: 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997;79:2282-2308.
6.
Gambichler T, Matip R, Moussa G, Altmeyer P, Hoffmann K: In vivo data of epidermal thickness evaluated by optical coherence tomography: effects of age, gender, skin type, and anatomic site. J Dermatol Sci 2006;44:145-152.
7.
Kleinpenning MM, Wolberink EW, Smits T, Blokx WAM, van de Kerkhof PCM, van Erp PEJ, Gerritsen RMJP: Fluorescence diagnosis in actinic keratosis and squamous cell carcinoma. Photoderm Photoimmun Photomed 2010;26:297-302.
8.
Dögnitz N, Salomon D, Zellweger M, Ballini JP, Gabrecht T, Lange N, van den Bergh H, Wagnières G: Comparison of ALA and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. J Photochem Photobiol B 2008;93:140-148.
9.
McLoone N, Donnelly RF, Walsh M, Dolan OM, McLoone S, McKenna K, McCarron PA: Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol Photoimmunol Photomed 2008;24:183-190.
10.
Ortiz-Policarpio B, Lui H: Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers. Skin Ther Lett 2009;14:1-3.
11.
Juzeniene A, Juzenas P, Ma LW, Iani V, Moan J: Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med Sci 2004;19:139-149.
12.
Pariser D, Loss R, Jarratt M, Abramovits W, Spencer J, Geronemus R, Bailin P, Bruce S: Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008;59:569-576.
13.
Szeimies RM, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klövekorn W, Fesq H, Berking C, Reifenberger J, Thaçi D: Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009;35:586-592.
14.
Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM: A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005;85:424-428.
15.
Ericson MB, Wennberg AM, Larkö O: Review of photo-dynamic therapy in actinic keratosis and basal cell carcinoma. Ther Clin Risk Manag 2008;4:1-9.
16.
Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR: Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001;45:96-104.
17.
Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I, Walton S, Kerrouche N, Thomas G, Soto P: Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006;155:1029-1036.
18.
Kleinpenning MM, van de Kerkhof PCM, Gerritsen RMJP: The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp. J Dermatol Treat 2010;21:252-257.
19.
Robinson DJ, de Bruijn HS, van der Veen N, Stringer MR, Brown SB, Star WM: Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol 1998;67:140-149.
20.
Braichotte DR, Savary JF, Monnier P, van den Bergh HE: Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg Med 1996;19:340-346.
21.
Glanzmann T, Hadjur C, Zellweger M, Grosiean P, Forrer M, Ballini JP, Monnier P, van den Bergh H, Lim CK, Wagnières G: Pharmacokinetics of tetra(m-hydroxyphenyl)chlorin in human plasma and individualized light dosimetry in photodynamic therapy. Photochem Photobiol 1998;67:596-602.
22.
Laubach HJ, Chang SK, Lee S, Rizvi I, Zurakowski D, Davis SJ, Taylor CR, Hasan T: In-vivo singlet oxygen dosimetry of clinical 5-aminolevulinic acid photodynamic therapy. J Biomed Opt 2008;13:050504.
23.
Niedre MJ, Yu CS, Patterson MS, Wilson BC: Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid. Br J Cancer 2005;92:298-304.
24.
Wilson B, Patterson M, Lilge L: Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci 1997;12:182-199.
25.
Zhu TC, Finlay JC: The role of photodynamic therapy (PDT) physics. Med Phys 2008;35:3127-3136.
26.
Themstrup L, Banzhaf C, Mogensen M, Jemec GBE: Cryosurgery treatment of actinic keratoses monitored by optical coherence tomography: a pilot study. Dermatology 2012;225:242-247.
27.
Ascencio M, Collinet P, Farine MO, Mordon S: Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg Med 2008;40:332-341.
28.
Dysart JS, Patterson MS: Photobleaching kinetics, photoproduct formation, and dose estimation during ALA induced PpIX PDT of MLL cells under well oxygenated and hypoxic conditions. Photochem Photobiol Sci 2006;5:73-81.
29.
Ericson MB, Sandberg C, Stenquist B, Gudmundson F, Karlsson M, Ros AM, Rosén A, Larkö O, Wennberg AM, Rosdahl I: Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004;151:1204-1212.
30.
Georgakoudi I, Nichols MG, Foster TH: The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol 1997;65:135-144.
31.
Sheng C, Hoopes PJ, Hasan T, Pogue BW: Photobleaching-based dosimetry predicts deposited dose in ALA-PpIX PDT of rodent esophagus. Photochem Photobiol 2007;83:738-748.
32.
De Berker D, McGregor JM, Hughes BR: Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-230.
33.
Gerritsen MJP, Smits T, Kleinpenning MM, van de Kerkhof PCM, van Erp PEJ: Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009;218:193-202.
34.
Morton CA: Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls. J Dermatolog Treat 2003;14(suppl 3):23-26.
35.
Wiegell SR, Skiveren J, Philipsen PA, Wulf HC: Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008;158:727-733.
36.
Moseley H: Light distribution and calibration of commercial PDT LED arrays. Photochem Photobiol Sci 2005;4:911-914.
37.
Sandberg C, Stenquist B, Rosdahl I, Ros AM, Synnerstad I, Karlsson M, Gudmundson F, Ericson MB, Larkö O, Wennberg AM: Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006;86:404-408.
38.
Virgili A, Osti F, Maranini C, Corazza M: Photodynamic therapy: parameters predictive of pain. Br J Dermatol 2010;162:460-461.
39.
Wiegell SR, Haedersdal M, Wulf HC: Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. Acta Derm Venereol 2009;89:145-149.
40.
Barge J, Glanzmann T, Zellweger M, Salomon S, van den Bergh H, Wagnières G: Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives. Photodiagn Photodyn Ther, submitted.
41.
Johnson C: Measuring pain. Visual analog scale versus numeric pain scale: what is the difference? J Chiropr Med 2005;4:43-44.
42.
Langley GB, Sheppeard H: The visual analogue scale: its use in pain measurement. Rheumatol Int 1985;5:145-148.
43.
Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, Sidoroff A, Hempel M, Ulrich J, Proebstle T, Meffert H, Mulder M, Salomon D, Dittmar HC, Bauer JW, Kernland K, Braathen L: Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-262.
44.
Fernández-Guarino M, Harto A, Sánchez-Ronco M, Pérez-García B, Marquet A, Jaén P: Retrospective, descriptive, observational study of treatment of multiple actinic keratoses with topical methyl aminolevulinate and red light: results in clinical practice and correlation with fluorescence imaging. Actas Dermosifiliogr 2008;99:779-787.
45.
Tyrrell J, Campbell S, Curnow A: Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy. Photodiagn Photodyn Ther 2010;7:232-238.
46.
Tyrrell JS, Campbell SM, Curnow A: The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med 2010;42:613-619.
47.
Angell-Petersen E, Sørensen R, Warloe T, Soler AM, Moan J, Peng Q, Giercksky KE: Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Invest Dermatol 2006;126:265-271.
48.
Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P: Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003;170:428-432.
49.
Wiegell SR, Stender IM, Na R, Wulf HC: Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003;139:1173-1177.
50.
Smits T, Robles CA, van Erp PEJ, van de Kerkhof PCM, Gerritsen MJP: Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid. J Invest Dermatol 2005;125:833-839.
51.
Anwar J, Wrone DA, Kimyai-Asadi A, Alam M: The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 2004;22:189-196.
52.
Cockerell CJ, Wharton JR: New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol 2005;4:462-467.
53.
Cottrell WJ, Paquette AD, Keymel KR, Foster TH, Oseroff AR: Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008;14:4475-4483.
54.
Grapengiesser S, Ericson M, Gudmundsson F, Larkö O, Rosén A, Wennberg AM: Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002;27:493-497.
55.
Jemec GBE: A simple method for routine measure of photodynamic therapy-associated pain. Photodermatol Photoimmunol Photomed 2010;26:51-52.
56.
Warren CB, Karai LJ, Vidimos A, Maytin EV: Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol 2009;61:1033-1043.
57.
Gholam P, Denk K, Sehr T, Enk A, Hartmann M: Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol 2010;63:213-218.
58.
Ericson MB, Grapengiesser S, Gudmundson F, Wennberg AM, Larkö O, Moan J, Rosén A: A spectroscopic study of the photobleaching of protoporphyrin IX in solution. Lasers Med Sci 2003;18:56-62.
59.
Sørensen R, Iani V, Moan J: Kinetics of photobleaching of protoporphyrin IX in the skin of nude mice exposed to different fluence rates of red light. Photochem Photobiol 1998;68:835-840.
60.
Zeng H, MacAulay C: Fluorescence spectroscopy and imaging for skin cancer detection and evaluation; in Mycek MA, Pogue BW (eds): Handbook of Biomedical Fluorescence. New York, Dekker, 2003, p 333.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.